Literature DB >> 1396545

Valproic acid treatment of experimental status epilepticus.

N Y Walton1, D M Treiman.   

Abstract

The efficacy of valproic acid (VPA) in control of generalized convulsive status epilepticus was tested in a rat model. Rats with cortical cobalt lesions were injected with homocysteine thiolactone to induce secondarily generalized tonic-clonic seizures (GTCS). The median effective dose (ED50) for control of GTCS was 211.9 mg/kg (270 micrograms/ml in serum 30 min post dose) when treatment was given intraperitoneally after the second GTCS. VPA entered both serum and brain very rapidly after injection, with little change in concentration from 5 to 30 min post dose. In earlier experiments with phenytoin, phenobarbital, diazepam and lorazepam in this model, we found that the serum concentrations produced by the ED50s versus GTCS were very similar to those which have been reported to be effective in treating human status epilepticus. If this same relationship holds true for VPA, we would predict that a serum concentration of around 270 micrograms/ml VPA would be required for control of generalized convulsive status epilepticus in human patients. The safety of this high a concentration of VPA has not been tested.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1396545     DOI: 10.1016/0920-1211(92)90074-4

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  9 in total

1.  Convulsive Status Epilepticus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-09       Impact factor: 3.598

2.  Intravenous valproate for status epilepticus ... An effective, yet still merely empirical alternative!

Authors:  Andres M Kanner
Journal:  Epilepsy Curr       Date:  2008 May-Jun       Impact factor: 7.500

3.  Antiepileptic drugs and apoptotic neurodegeneration in the developing brain.

Authors:  Petra Bittigau; Marco Sifringer; Kerstin Genz; Ellen Reith; Dana Pospischil; Suresh Govindarajalu; Mark Dzietko; Stefanie Pesditschek; Ingrid Mai; Krikor Dikranian; John W Olney; Chrysanthy Ikonomidou
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-04       Impact factor: 11.205

Review 4.  Pharmacotherapy for Refractory and Super-Refractory Status Epilepticus in Adults.

Authors:  Martin Holtkamp
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 5.  [Refractory status epilepticus: diagnosis, therapy, course, and prognosis].

Authors:  F Bösebeck; G Möddel; K Anneken; M Fischera; S Evers; E B Ringelstein; C Kellinghaus
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

6.  Animal models for the development of new neuropharmacological therapeutics in the status epilepticus.

Authors:  Ed Martín; Ma Pozo
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

Review 7.  Pharmacotherapy for Status Epilepticus.

Authors:  Eugen Trinka; Julia Höfler; Markus Leitinger; Francesco Brigo
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

8.  Locally applied valproate enhances survival in rats after neocortical treatment with tetanus toxin and cobalt chloride.

Authors:  Dirk-Matthias Altenmüller; Jonas M Hebel; Michael P Rassner; Silvanie Volz; Thomas M Freiman; Thomas J Feuerstein; Josef Zentner
Journal:  Biomed Res Int       Date:  2013-09-14       Impact factor: 3.411

9.  Chronotolerance study of the antiepileptic drug valproic acid in mice.

Authors:  Wafa Ben-Cherif; Ichrak Dridi; Karim Aouam; Mossadok Ben-Attia; Alain Reinberg; Naceur A Boughattas
Journal:  J Circadian Rhythms       Date:  2012-05-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.